130265 20240124152850.0 doi 10.1007/s00268-011-1078-7 sideral 73978 ART-2011-73978 eng García-Gil, F. A. Universidad de Zaragoza (orcid)0000-0002-8275-7191 Celsior Versus University of Wisconsin Preserving Solutions for Liver Transplantation: Postreperfusion Syndrome and Outcome of a 5-Year Prospective Randomized Controlled Study 2011 Background: Celsior solution (CS) is a high-sodium, low-potassium, low-viscosity extracellular solution that has been used for liver graft preservation in recent years, although experience with it is still limited. We performed an open-label randomized active-controlled trial comparing CS with the University of Wisconsin solution (UW) for liver transplantation (LT), with a follow-up period of 5 years. Methods: Adult transplant recipients (n = 102) were prospectively randomized to receive either CS (n = 51) or UW (n = 51). The two groups were comparable with respect to donor and recipient characteristics. The primary outcome measure was the incidence of postreperfusion syndrome (PRS). Secondary outcome measures included primary nonfunction (PNF) or primary dysfunction (PDF), liver retransplantation, and graft and patient survival. Other secondary outcome measures were days in the intensive care unit (ICU) and the rates of acute rejection, chronic rejection, infectious complications, postoperative reoperations, and vascular and biliary complications. Results In all, 14 posttransplant variables revealed no significant differences between the groups. There were no cases of PNF or PDF. The incidence of PRS was 5.9% in the CS group and 21.6% in the UW group (P = 0.041). After reperfusion, CS revealed greater control of serum potassium (P = 0.015), magnesium levels (P = 0.005), and plasma glucose (P = 0.042) than UW. Respective patient survivals at 3, 12, and 60 months were 95.7, 87.2, and 82.0% for the CS group and 95.7, 83.3, and 66.6% for the UW group (P = 0.123). Conclusions While retaining the same degree of safety and effectiveness as UW for LT, CS may yield postliver graft reperfusion benefits, as shown in this study by a significant reduction in the incidence of PRS and greater metabolic control. info:eu-repo/semantics/closedAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 2.362 2011 SURGERY 48 / 199 = 0.241 2011 Q1 T1 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Serrano, M. T. (orcid)0000-0002-7119-2244 Fuentes-Broto, L. Universidad de Zaragoza (orcid)0000-0003-2656-6750 Arenas, J. García, J. J. Universidad de Zaragoza (orcid)0000-0001-9507-6478 Güemes, A. Universidad de Zaragoza (orcid)0000-0002-4437-2581 Bernal, V. Campillo, A. Sostres, C. Araiz, J. J. Universidad de Zaragoza (orcid)0000-0001-6033-2216 Royo, P. Simón, M. A. 1005 410 Universidad de Zaragoza Dpto. Farmacología y Fisiolog. Área Fisiología 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 1004 090 Universidad de Zaragoza Dpto. Cirugía,Ginecol.Obstetr. Área Cirugía 35, 7 (2011), 1598-1607 World j. surg. WORLD JOURNAL OF SURGERY 0364-2313 337462 http://zaguan.unizar.es/record/130265/files/texto_completo.pdf Versión publicada 2268698 http://zaguan.unizar.es/record/130265/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:130265 articulos driver 2024-01-24-14:58:06 ARTICLE